那他珠单抗治疗多发性硬化症。
Natalizumab in the treatment of multiple sclerosis.
机构信息
Cantonal Hospital, St. Gallen, Switzerland.
出版信息
Ther Adv Neurol Disord. 2009 Mar;2(2):115-28. doi: 10.1177/1756285608101861.
Abstract
Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42-54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing-remitting multiple sclerosis (RRMS). Natalizumab is generally well tolerated, but due to rare and potentially fatal side-effects, it was approved with a restricted-distribution format in 2006. Expert statements and the European Medical Agency recommend the use of natalizumab after failure of first-line disease-modifying therapies in patients with relapsing forms of MS. As part of the risk management plan, worldwide extensive safety programmes aim to provide more data on natalizumab safety in clinical practice. At the end of September 2008, 48 000 patients have received natalizumab and 18000 patients are on treatment for at least 1 year. The assessment of risk and benefit is still ongoing.
摘要
那他珠单抗在 III 期关键性临床试验（AFFIRM）中使复发缓解型多发性硬化症（RRMS）患者的一年临床复发率降低了 68%，两年持续残疾进展的风险降低了 42-54%。那他珠单抗通常具有良好的耐受性，但由于罕见且可能致命的副作用，它于 2006 年以限制分发的形式获得批准。专家声明和欧洲药品管理局建议在复发型 MS 患者一线疾病修正治疗失败后使用那他珠单抗。作为风险管理计划的一部分，全球广泛的安全计划旨在提供更多那他珠单抗在临床实践中的安全性数据。截至 2008 年 9 月底，已有 48000 名患者接受了那他珠单抗治疗，18000 名患者的治疗时间至少为 1 年。风险和收益的评估仍在进行中。
相似文献
1
Natalizumab in the treatment of multiple sclerosis.那他珠单抗治疗多发性硬化症。
Ther Adv Neurol Disord. 2009 Mar;2(2):115-28. doi: 10.1177/1756285608101861.
2
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3.
3
Natalizumab for relapsing remitting multiple sclerosis.那他珠单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007621. doi: 10.1002/14651858.CD007621.pub2.
4
Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.在英国，将那他珠单抗（泰萨比）与其他改善病情疗法用于高度活动性复发缓解型多发性硬化症患者的成本效益分析。
Pharmacoeconomics. 2008;26(7):617-27. doi: 10.2165/00019053-200826070-00008.
5
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.在沙特阿拉伯，对那他珠单抗、利妥昔单抗和奥瑞珠单抗治疗复发缓解型多发性硬化症的临床和经济评价。
BMC Health Serv Res. 2023 May 26;23(1):552. doi: 10.1186/s12913-023-09462-z.
6
Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.那他珠单抗：用于治疗复发缓解型多发性硬化症的综述。
Drugs. 2013 Sep;73(13):1463-81. doi: 10.1007/s40265-013-0102-7.
7
Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.那他珠单抗治疗非洲裔复发型多发性硬化症患者的疗效：AFFIRM和SENTINEL数据分析
Arch Neurol. 2011 Apr;68(4):464-8. doi: 10.1001/archneurol.2011.45.
8
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.用于多发性硬化症的免疫调节剂和免疫抑制剂：一项网状Meta分析
Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD008933. doi: 10.1002/14651858.CD008933.pub2.
9
Rituximab for relapsing-remitting multiple sclerosis.利妥昔单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
10
Mitoxantrone: a review of its use in multiple sclerosis.米托蒽醌：其在多发性硬化症中的应用综述
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
引用本文的文献
1
Natalizumab-associated progressive multifocal leukoencephalopathy.那他珠单抗相关的进行性多灶性白质脑病
Front Neurol. 2025 Jun 20;16:1575653. doi: 10.3389/fneur.2025.1575653. eCollection 2025.
2
A 62-Year-Old Male Patient With Spinal Lesions Following Fingolimod Discontinuation in the Setting of Disseminated Shingles.一名62岁男性患者，在停用芬戈莫德后出现脊髓病变，同时伴有播散性带状疱疹。
Cureus. 2025 May 21;17(5):e84587. doi: 10.7759/cureus.84587. eCollection 2025 May.
3
The Probable Infectious Origin of Multiple Sclerosis.多发性硬化症可能的感染起源
NeuroSci. 2023 Sep 7;4(3):211-234. doi: 10.3390/neurosci4030019. eCollection 2023 Sep.
4
Stem Cell-Derived Exosomal MicroRNAs as Novel Potential Approach for Multiple Sclerosis Treatment.干细胞衍生的外泌体 microRNAs 作为多发性硬化症治疗的新的潜在方法。
Cell Mol Neurobiol. 2024 May 7;44(1):44. doi: 10.1007/s10571-024-01478-1.
5
Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy.为计划怀孕的临床稳定型复发缓解型多发性硬化症患者更换治疗方案。
Mult Scler J Exp Transl Clin. 2021 Mar 19;7(1):20552173211001571. doi: 10.1177/20552173211001571. eCollection 2021 Jan-Mar.
6
Transcriptomic and clonal characterization of T cells in the human central nervous system.人类中枢神经系统 T 细胞的转录组和克隆特征。
Sci Immunol. 2020 Sep 18;5(51). doi: 10.1126/sciimmunol.abb8786.
7
Role of Viruses in the Pathogenesis of Multiple Sclerosis.病毒在多发性硬化症发病机制中的作用。
Viruses. 2020 Jun 13;12(6):643. doi: 10.3390/v12060643.
8
Molecular Interventions towards Multiple Sclerosis Treatment.多发性硬化症治疗的分子干预措施
Brain Sci. 2020 May 15;10(5):299. doi: 10.3390/brainsci10050299.
9
Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?用于治疗脑转移瘤的抗体，是梦想还是现实？
Pharmaceutics. 2020 Jan 13;12(1):62. doi: 10.3390/pharmaceutics12010062.
10
B cell checkpoints in autoimmune rheumatic diseases.B 细胞检查点在自身免疫性风湿病中的作用。
Nat Rev Rheumatol. 2019 May;15(5):303-315. doi: 10.1038/s41584-019-0211-0.
本文引用的文献
1
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.那他珠单抗作为二线治疗药物，在复发缓解型多发性硬化症的治疗中疗效显著。
Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x.
2
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.那他珠单抗导致脑周血管间隙中树突状细胞和CD4 + T细胞数量减少。
Arch Neurol. 2008 Dec;65(12):1596-603. doi: 10.1001/archneur.65.12.noc80051. Epub 2008 Oct 13.
3
More on melanoma with transdifferentiation.更多关于伴有转分化的黑色素瘤的内容。
N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089.
4
Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.在英国，将那他珠单抗（泰萨比）与其他改善病情疗法用于高度活动性复发缓解型多发性硬化症患者的成本效益分析。
Pharmacoeconomics. 2008;26(7):617-27. doi: 10.2165/00019053-200826070-00008.
5
Allergic and nonallergic delayed infusion reactions during natalizumab therapy.那他珠单抗治疗期间的过敏和非过敏迟发性输注反应。
Arch Neurol. 2008 May;65(5):656-8. doi: 10.1001/archneur.65.5.656.
6
Is natalizumab overshooting its rebound?那他珠单抗是否矫枉过正？
Neurology. 2008 Mar 25;70(13 Pt 2):1073-4. doi: 10.1212/01.wnl.0000306415.37679.5a.
7
Melanoma complicating treatment with natalizumab for multiple sclerosis.黑色素瘤使那他珠单抗治疗多发性硬化症变得复杂。
N Engl J Med. 2008 Feb 7;358(6):647-8. doi: 10.1056/NEJMc0706103.
8
Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient.一名获得性免疫缺陷综合征患者的进行性多灶性白质脑病的脊髓病变
J Neurovirol. 2007 Oct;13(5):474-6. doi: 10.1080/13550280701469178.
9
Reply to "'Thinking without thinking' about natalizumab and PML".对“关于那他珠单抗与进行性多灶性白质脑病的‘不假思索的思考’”的回复
J Neurol Sci. 2008 Jan 15;264(1-2):198-9; author reply 199. doi: 10.1016/j.jns.2007.09.019. Epub 2007 Oct 15.
10
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies.与早期形成中和抗体相关的那他珠单抗延迟过敏反应。
Arch Neurol. 2007 Sep;64(9):1331-3. doi: 10.1001/archneur.64.9.1331.
Zotero 插件